Warfarin Dosing Issues Emerge In Early Results From Medco/Mayo Research
Executive Summary
Nearly three-fourths of early patient participants in a warfarin research project appear to need non-standard dosing of the drug based on genetic screening, Medco reported during its analyst day presentation Nov. 16
You may also be interested in...
Medco Personalized Medicine Research Shows “Real World” Promise – Frueh
Medco's research can advance the cause of personalized medicine by proving its benefits in a "real world" setting, according to Felix Frueh, the firm's new VP of research and development for personalized medicine
Medco Personalized Medicine Research Shows “Real World” Promise – Frueh
Medco's research can advance the cause of personalized medicine by proving its benefits in a "real world" setting, according to Felix Frueh, the firm's new VP of research and development for personalized medicine
Personalized Medicine Not Paying The Bills Yet; More Science Needed
Though the promise of personalized medicine has been widely touted, firms focusing on targeted therapies and companion diagnostics are not getting much bang for their buck - yet